Ivacaftor Aliud

Ivacaftor, the active ingredient in Ivacaftor Aliud, is a CFTR potentiator presented as an oral tablet for oral use. It treats cystic fibrosis in patients who carry specific gating mutations such as G551D, improving chloride transport in affected cells.

GNH USA supplies Ivacaftor Aliud as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑controlled manufacturing, regulatory compliance, and reliable logistics for global distribution. Our network includes procurement teams in Europe, North America and Asia, facilitating timely access to essential cystic fibrosis therapies.

Ivacaftor is a CFTR potentiator used in the management of cystic fibrosis, targeting the underlying protein defect. - Cystic fibrosis with G551D gating mutation: improves lung function and reduces frequency of pulmonary exacerbations. - Cystic fibrosis with other responsive gating mutations (e.g., R117H): enhances chloride transport, leading to better respiratory outcomes. - Cystic fibrosis with residual function mutations (when clinically appropriate): increases CFTR activity, supporting nutritional status and sweat chloride reduction. - Cystic fibrosis patients eligible for monotherapy: provides an oral treatment option that addresses the basic defect in CFTR gating.

Ivacaftor may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Diarrhea: watery stools, may be self‑limiting. - Nausea: occasional, usually resolves without intervention. - Upper respiratory tract infection: symptoms of cold or mild sinusitis. - Abdominal pain: cramp‑like discomfort in the stomach area. - Fatigue: feeling of tiredness or reduced energy. - Vomiting: occasional episodes, generally mild.

Serious or Rare Side Effects: - Elevated liver enzymes (ALT/AST): may indicate hepatic stress, requires monitoring. - Cataracts: lens opacity developing over prolonged use, ophthalmologic evaluation advised. - Severe rash or hypersensitivity reactions: includes Stevens‑Johnson syndrome, requires immediate medical attention.

When prescribing ivacaftor, clinicians should consider several precautionary measures to ensure safe use. - Liver function monitoring: assess baseline ALT/AST and repeat periodically during therapy. - Drug interaction awareness: avoid concomitant use with strong CYP3A inducers or adjust dose if necessary. - Pregnancy and lactation: weigh potential benefits against unknown risks; discuss with patient. - Renal impairment: use with caution in patients with severe kidney dysfunction, monitor renal parameters. - Store at room temperature: keep tablets in the original container, protect from moisture and direct sunlight.

Ivacaftor is metabolized primarily by CYP3A enzymes, leading to clinically relevant drug interactions.

Major Interactions (Avoid): - Strong CYP3A inducers (e.g., rifampin, carbamazepine): markedly reduce ivacaftor exposure, compromising efficacy. - Strong CYP3A inhibitors (e.g., ketoconazole, itraconazole): significantly increase ivacaftor levels, raising risk of toxicity. - Certain statins (e.g., simvastatin, lovastatin): increased statin exposure may cause myopathy.

Moderate Interactions (Monitor Closely): - Oral contraceptives: ivacaftor may lower hormone levels, reducing contraceptive effectiveness. - Antacids containing aluminum or magnesium: may affect ivacaftor absorption; separate administration by at least 2 hours. - Warfarin: monitor INR more frequently as ivacaftor may alter anticoagulant effect.